Literature DB >> 21235613

Use of moderate sedation for a patient with Down syndrome, intellectual disability, and Eisenmenger syndrome: a case report.

Teruhito Kunimatsu1, Setsue Greenan, Anzu Yamashita, Toshiharu Yamamoto, Masakazu Ikeda.   

Abstract

For patients who have Eisenmenger syndrome (ES), perioperative risks are high even for noncardiac surgery, such as dental extractions. We report on the case history of a 38-year-old male patient with Down syndrome (DS), intellectual disability (ID), and ES. The patient was scheduled for extraction of the right maxillary second molar tooth. His physical health was poor. Following oxygenation, midazolam was administered intravenously very slowly until the optimum sedative level was obtained, with a total dosage of 3.5 mg. There were no marked changes in vital signs during the perioperative period, and the patient was discharged the same day. This case suggests that moderate or conscious sedation using midazolam for dental treatment of a patient with DS, ID, and ES was well tolerated. Several critical points are presented in this review. ©2010 Special Care Dentistry Association and Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21235613     DOI: 10.1111/j.1754-4505.2010.00171.x

Source DB:  PubMed          Journal:  Spec Care Dentist        ISSN: 0275-1879


  3 in total

1.  Dental considerations and recommendations in Eisenmenger syndrome: A report of an unusual paediatric case.

Authors:  P A Calderón-Ávila; J A Garrocho-Rangel; J A Cepeda-Bravo; M S Ruiz-Rodríguez; M Pierdant-Pérez; A Pozos-Guillén
Journal:  Eur Arch Paediatr Dent       Date:  2018-09-08

2.  Deep sedation for dental treatment in a Down syndrome patient with Eisenmenger syndrome: A case report.

Authors:  Seong In Chi; Hyun Jeong Kim; Kwang-Suk Seo
Journal:  J Dent Anesth Pain Med       Date:  2016-03-31

Review 3.  Perioperative care of adults with Down syndrome: a narrative review.

Authors:  Elizabeth B Malinzak
Journal:  Can J Anaesth       Date:  2021-06-24       Impact factor: 6.713

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.